Therapeutic role of rifampicin in Alzheimer's disease

Rifampicin exerts significant brain protective functions in multiple experimental models. Here we summarize the underlying mechanisms of the neuroprotective and pro‐cognitive effects of rifampicin that are mediated by its anti‐inflammatory, anti‐tau, anti‐amyloid, and cholinergic effects. Beyond sug...

Full description

Saved in:
Bibliographic Details
Published inPsychiatry and clinical neurosciences Vol. 72; no. 3; pp. 152 - 159
Main Authors Yulug, Burak, Hanoglu, Lütfü, Ozansoy, Mehmet, Isık, Dogan, Kilic, Ulkan, Kilic, Ertugrul, Schabitz, Wolf Rüdiger
Format Journal Article
LanguageEnglish
Published Melbourne John Wiley & Sons Australia, Ltd 01.03.2018
Wiley Subscription Services, Inc
Subjects
Alzheimer Disease - drug therapy
Alzheimer's disease
amyloid beta clearance
Cognitive ability
Humans
Inflammation
Neurodegenerative diseases
Neuroimaging
Neuroprotection
Neuroprotective Agents - pharmacology
Nootropic Agents - pharmacology
oligomeric amyloid hypothesis
rifampicin
Rifampin
Rifampin - pharmacology
Tau protein
rifampicin
amyloid beta clearance
oligomeric amyloid hypothesis
Alzheimer's disease
neuroprotection
Online AccessGet full text
ISSN1323-1316
1440-1819
1440-1819
DOI10.1111/pcn.12637

Cover

Abstract Rifampicin exerts significant brain protective functions in multiple experimental models. Here we summarize the underlying mechanisms of the neuroprotective and pro‐cognitive effects of rifampicin that are mediated by its anti‐inflammatory, anti‐tau, anti‐amyloid, and cholinergic effects. Beyond suggesting that rifampicin shows strong brain protective effects in preclinical models of Alzheimer's disease, we also provide substantial clinical evidence for the neuroprotective and pro‐cognitive effects of rifampicin. Future neuroimaging studies combined with clinical assessment scores are the following steps to be taken in this field of research.
AbstractList Rifampicin exerts significant brain protective functions in multiple experimental models. Here we summarize the underlying mechanisms of the neuroprotective and pro‐cognitive effects of rifampicin that are mediated by its anti‐inflammatory, anti‐tau, anti‐amyloid, and cholinergic effects. Beyond suggesting that rifampicin shows strong brain protective effects in preclinical models of Alzheimer's disease, we also provide substantial clinical evidence for the neuroprotective and pro‐cognitive effects of rifampicin. Future neuroimaging studies combined with clinical assessment scores are the following steps to be taken in this field of research.
Rifampicin exerts significant brain protective functions in multiple experimental models. Here we summarize the underlying mechanisms of the neuroprotective and pro-cognitive effects of rifampicin that are mediated by its anti-inflammatory, anti-tau, anti-amyloid, and cholinergic effects. Beyond suggesting that rifampicin shows strong brain protective effects in preclinical models of Alzheimer's disease, we also provide substantial clinical evidence for the neuroprotective and pro-cognitive effects of rifampicin. Future neuroimaging studies combined with clinical assessment scores are the following steps to be taken in this field of research.Rifampicin exerts significant brain protective functions in multiple experimental models. Here we summarize the underlying mechanisms of the neuroprotective and pro-cognitive effects of rifampicin that are mediated by its anti-inflammatory, anti-tau, anti-amyloid, and cholinergic effects. Beyond suggesting that rifampicin shows strong brain protective effects in preclinical models of Alzheimer's disease, we also provide substantial clinical evidence for the neuroprotective and pro-cognitive effects of rifampicin. Future neuroimaging studies combined with clinical assessment scores are the following steps to be taken in this field of research.
Author Kilic, Ertugrul
Schabitz, Wolf Rüdiger
Yulug, Burak
Hanoglu, Lütfü
Ozansoy, Mehmet
Isık, Dogan
Kilic, Ulkan
Author_xml – sequence: 1
  givenname: Burak
  orcidid: 0000-0002-9704-6173
  surname: Yulug
  fullname: Yulug, Burak
  email: burakyulug@gmail.com
  organization: Istanbul Medipol University
– sequence: 2
  givenname: Lütfü
  surname: Hanoglu
  fullname: Hanoglu, Lütfü
  organization: Istanbul Medipol University
– sequence: 3
  givenname: Mehmet
  surname: Ozansoy
  fullname: Ozansoy, Mehmet
  organization: Istanbul Medipol University
– sequence: 4
  givenname: Dogan
  surname: Isık
  fullname: Isık, Dogan
  organization: Istanbul Medipol University
– sequence: 5
  givenname: Ulkan
  surname: Kilic
  fullname: Kilic, Ulkan
  organization: Faculty of Medicine, University of Health Sciences
– sequence: 6
  givenname: Ertugrul
  surname: Kilic
  fullname: Kilic, Ertugrul
  organization: Istanbul Medipol University
– sequence: 7
  givenname: Wolf Rüdiger
  surname: Schabitz
  fullname: Schabitz, Wolf Rüdiger
  organization: Bethel, EVKB, Bielefeld, University of Münster
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29315976$$D View this record in MEDLINE/PubMed
BookMark eNp1kMtKAzEUhoNU1FYXvoAMuFAXo7lMJpNlKd5A1EVdhyQ9Q1PmZjKD1Kc32ropGg4khO__OXxjNGraBhA6JfiaxHPT2eaa0JyJPXREsgynpCByFN-MspQwkh-icQgrjDFjOTlAh1QywqXIjxCfL8HrDobe2cS3FSRtmXhX6rpz1jVJnGn1uQRXg78IycIF0AGO0X6pqwAn23uC3u5u57OH9Onl_nE2fUptJgqRkgXRJudU6MJYg3mRl4uCaWOZFCYT8Z8JI5jhmNNSUJCa8ZyXVAppJJXAJuhy09v59n2A0KvaBQtVpRtoh6CILCTnBSMyouc76KodfBO3UxRHSRkusixSZ1tqMDUsVOddrf1a_QqJwM0GsL4NwUOprOt179qm99pVimD1rVxF5epHeUxc7SR-S_9it-0froL1_6B6nT1vEl8T0Yzy
CitedBy_id crossref_primary_10_1016_j_cyto_2018_10_016
crossref_primary_10_2174_1381612826666200113162641
crossref_primary_10_3389_fnins_2022_822420
crossref_primary_10_1002_bkcs_11449
crossref_primary_10_1007_s12035_020_02058_2
crossref_primary_10_3390_ph13090242
crossref_primary_10_3390_antiox11112141
crossref_primary_10_3233_JAD_201046
crossref_primary_10_1016_j_ejphar_2021_173974
crossref_primary_10_2174_1874467215666220222105004
crossref_primary_10_1016_j_ijbiomac_2022_11_031
crossref_primary_10_3233_JAD_210080
crossref_primary_10_1007_s00702_021_02457_2
crossref_primary_10_3389_fphar_2024_1415951
crossref_primary_10_1007_s00421_024_05496_1
crossref_primary_10_30565_medalanya_553846
crossref_primary_10_1016_j_addr_2022_114418
crossref_primary_10_1016_j_bbi_2019_10_014
crossref_primary_10_1097_CM9_0000000000001706
crossref_primary_10_3389_fnagi_2024_1485657
crossref_primary_10_31887_DCNS_2019_21_2_vhede
crossref_primary_10_3389_fimmu_2021_683068
crossref_primary_10_1039_D1NP00067E
crossref_primary_10_1016_j_drudis_2022_04_003
crossref_primary_10_4103_1673_5374_389745
crossref_primary_10_1177_11795735251322450
crossref_primary_10_3390_nu13010037
crossref_primary_10_3390_s23020976
crossref_primary_10_1016_j_lfs_2023_122022
crossref_primary_10_3390_ijms21144920
crossref_primary_10_2174_2589977513666210315095133
crossref_primary_10_3389_fnagi_2022_833365
crossref_primary_10_1186_s12974_019_1494_4
crossref_primary_10_1080_07391102_2022_2154842
crossref_primary_10_3390_molecules26247456
crossref_primary_10_3389_fphar_2024_1459655
crossref_primary_10_1093_ckj_sfae174
crossref_primary_10_3389_fnagi_2022_1018371
crossref_primary_10_3390_cells12030429
crossref_primary_10_1021_acschemneuro_2c00371
crossref_primary_10_1016_j_phrs_2025_107693
crossref_primary_10_1007_s12264_021_00730_8
crossref_primary_10_1016_j_pbb_2020_172892
crossref_primary_10_3390_ijms24044047
crossref_primary_10_3389_fnagi_2021_701899
crossref_primary_10_3390_jpm12101731
crossref_primary_10_1016_j_arr_2024_102229
crossref_primary_10_1016_j_crphar_2021_100022
crossref_primary_10_1016_j_expneurol_2019_113159
crossref_primary_10_3390_ijms24065914
crossref_primary_10_1016_j_arr_2024_102544
crossref_primary_10_1016_j_neubiorev_2022_104814
crossref_primary_10_3390_ijms21207551
crossref_primary_10_7759_cureus_52435
crossref_primary_10_4110_in_2020_20_e47
crossref_primary_10_35414_akufemubid_1332018
Cites_doi 10.1097/WNR.0b013e32830b3661
10.1016/j.nbd.2004.12.013
10.4196/kjpp.2009.13.6.475
10.2174/156720507780362245
10.1016/S0022-510X(99)00057-X
10.1056/NEJM199608013350507
10.1016/S0021-9258(19)37174-1
10.3389/fnagi.2014.00093
10.1124/mol.109.061754
10.2174/1567205013666160314151012
10.1523/JNEUROSCI.17-20-07736.1997
10.1093/brain/aww042
10.2174/1567205013666161201201227
10.18433/J36016
10.1016/S0092-8674(01)00286-0
10.1016/S0925-4439(00)00034-X
10.1002/(SICI)1098-1136(199603)16:3<276::AID-GLIA10>3.0.CO;2-X
10.1006/bbrc.1994.2428
10.1007/s10072-012-1156-0
10.1016/j.bbrc.2017.01.100
10.1016/j.chembiol.2004.08.025
10.1046/j.1471-4159.2002.00904.x
10.1016/j.neuron.2010.04.029
10.1111/j.1750-3639.2007.00075.x
10.1515/bmc-2016-0029
10.1159/000477343
10.1172/JCI10498
10.2165/00003088-197803020-00002
10.1016/j.brainres.2011.04.019
10.1016/j.neuropharm.2013.04.059
10.1016/0923-2494(92)80052-M
10.1016/0140-6736(92)92870-L
10.1016/j.neuroscience.2014.12.033
10.1007/s00401-004-0867-6
10.1016/j.bbadis.2006.03.002
10.1042/bj3220859
10.1111/j.1742-4658.2010.07564.x
10.1016/j.neuron.2008.01.003
10.1056/NEJM199906243402507
10.1016/j.brainresbull.2014.05.007
10.1046/j.1471-4159.2001.00113.x
10.1097/00008571-200210000-00005
10.1126/science.1566067
10.1111/j.1471-4159.2004.02385.x
10.2967/jnumed.113.130161
10.1073/pnas.91.8.3270
10.1016/j.nlm.2011.08.003
10.1002/gps.3846
10.1016/S1474-4422(13)70301-6
10.1590/S1807-59322011001300006
10.1074/jbc.271.12.6839
10.1172/JCI25247
10.1038/34910
10.1086/302553
10.1111/j.2042-7158.2011.01309.x
10.1007/s00401-013-1177-7
10.1021/bp060353n
10.1016/j.brainres.2006.12.074
10.1038/nm1635
10.1074/jbc.M109.057182
10.1111/j.1532-5415.2004.52109.x
10.1021/bi702518m
10.1056/NEJMra040223
10.3233/JAD-2012-120319
10.1093/jac/31.5.731
10.1016/S0002-9440(10)65184-X
ContentType Journal Article
Copyright 2018 The Authors. Psychiatry and Clinical Neurosciences © 2018 Japanese Society of Psychiatry and Neurology
2018 The Authors. Psychiatry and Clinical Neurosciences © 2018 Japanese Society of Psychiatry and Neurology.
2018 The Author. Psychiatry and Clinical Neurosciences © 2018 Japanese Society of Psychiatry and Neurology
Copyright_xml – notice: 2018 The Authors. Psychiatry and Clinical Neurosciences © 2018 Japanese Society of Psychiatry and Neurology
– notice: 2018 The Authors. Psychiatry and Clinical Neurosciences © 2018 Japanese Society of Psychiatry and Neurology.
– notice: 2018 The Author. Psychiatry and Clinical Neurosciences © 2018 Japanese Society of Psychiatry and Neurology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
K9.
7X8
DOI 10.1111/pcn.12637
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Neurosciences Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
CrossRef

MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1440-1819
EndPage 159
ExternalDocumentID 29315976
10_1111_pcn_12637
PCN12637
Genre reviewArticle
Journal Article
Review
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
123
1OB
1OC
29P
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5VS
66C
7.U
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABIVO
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFEBI
AFFPM
AFGKR
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AHEFC
AHMBA
AIACR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
DUUFO
E3Z
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
EPS
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TKC
TR2
TUS
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
X7M
XG1
YFH
ZXP
ZZTAW
~02
~IA
~WT
AAHHS
AAYXX
ACCFJ
AEEZP
AEQDE
AIWBW
AJBDE
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
K9.
7X8
ID FETCH-LOGICAL-c4787-1d1ab6527a8bcb0586fd83abc397b4727a37b73b5052f72e9a3565f2979b929e3
IEDL.DBID DR2
ISSN 1323-1316
1440-1819
IngestDate Fri Sep 05 05:41:11 EDT 2025
Fri Jul 25 07:08:19 EDT 2025
Thu Apr 03 07:02:22 EDT 2025
Thu Apr 24 23:12:20 EDT 2025
Tue Jul 01 03:51:17 EDT 2025
Sun Sep 21 06:21:34 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords rifampicin
amyloid beta clearance
oligomeric amyloid hypothesis
Alzheimer's disease
neuroprotection
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2018 The Authors. Psychiatry and Clinical Neurosciences © 2018 Japanese Society of Psychiatry and Neurology.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4787-1d1ab6527a8bcb0586fd83abc397b4727a37b73b5052f72e9a3565f2979b929e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-9704-6173
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/pcn.12637
PMID 29315976
PQID 2011140844
PQPubID 1106347
PageCount 8
ParticipantIDs proquest_miscellaneous_1989558319
proquest_journals_2011140844
pubmed_primary_29315976
crossref_citationtrail_10_1111_pcn_12637
crossref_primary_10_1111_pcn_12637
wiley_primary_10_1111_pcn_12637_PCN12637
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March 2018
PublicationDateYYYYMMDD 2018-03-01
PublicationDate_xml – month: 03
  year: 2018
  text: March 2018
PublicationDecade 2010
PublicationPlace Melbourne
PublicationPlace_xml – name: Melbourne
– name: Australia
– name: Tokyo
PublicationTitle Psychiatry and clinical neurosciences
PublicationTitleAlternate Psychiatry Clin Neurosci
PublicationYear 2018
Publisher John Wiley & Sons Australia, Ltd
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons Australia, Ltd
– name: Wiley Subscription Services, Inc
References 2017; 7
2017; 8
2013; 28
2002; 12
2013; 126
2011; 96
1999; 165
1978; 3
2011; 13
2006; 1762
2011; 14
2001; 104
2010; 66
2009; 13
2010; 277
1993; 31
2000; 1502
2011; 63
2011; 66
1997; 17
2014; 13
2007; 1139
2007; 4
1996; 335
2017; 485
2007; 23
2014; 6
2014; 55
2007; 17
2010; 77
1992; 340
2015; 288
1992; 267
2008; 19
2005; 115
2004; 89
1999; 340
2010; 285
1999; 65
2008; 57
2002; 81
2004; 108
1996; 16
2007; 13
2016; 13
2012; 31
2014; 107
1997; 322
2004; 11
1998; 391
2004; 52
2004; 351
1994; 204
2017; 14
2013; 34
2013; 73
2000; 106
1992; 256
2008; 47
1996; 271
2016; 139
2005; 3
1999; 155
1995; 143
1994; 91
2005; 18
2001; 76
e_1_2_9_31_1
e_1_2_9_52_1
e_1_2_9_50_1
e_1_2_9_10_1
e_1_2_9_35_1
e_1_2_9_56_1
e_1_2_9_12_1
e_1_2_9_33_1
e_1_2_9_54_1
e_1_2_9_39_1
Dyrks T (e_1_2_9_15_1) 1992; 267
e_1_2_9_16_1
e_1_2_9_37_1
e_1_2_9_58_1
e_1_2_9_18_1
e_1_2_9_41_1
e_1_2_9_64_1
e_1_2_9_20_1
e_1_2_9_62_1
e_1_2_9_22_1
e_1_2_9_68_1
e_1_2_9_24_1
e_1_2_9_66_1
e_1_2_9_8_1
e_1_2_9_6_1
e_1_2_9_60_1
e_1_2_9_2_1
e_1_2_9_26_1
e_1_2_9_49_1
e_1_2_9_28_1
e_1_2_9_47_1
e_1_2_9_30_1
Bi W (e_1_2_9_43_1) 2011; 13
e_1_2_9_53_1
e_1_2_9_51_1
e_1_2_9_11_1
e_1_2_9_34_1
e_1_2_9_57_1
e_1_2_9_13_1
e_1_2_9_32_1
e_1_2_9_55_1
Morrison AS (e_1_2_9_14_1) 2005; 3
e_1_2_9_38_1
e_1_2_9_17_1
e_1_2_9_36_1
e_1_2_9_59_1
e_1_2_9_19_1
e_1_2_9_42_1
e_1_2_9_63_1
e_1_2_9_40_1
e_1_2_9_61_1
e_1_2_9_21_1
e_1_2_9_46_1
e_1_2_9_67_1
e_1_2_9_23_1
e_1_2_9_44_1
e_1_2_9_65_1
e_1_2_9_7_1
e_1_2_9_5_1
Berkinbosch F (e_1_2_9_4_1) 1995; 143
e_1_2_9_3_1
Kim SK (e_1_2_9_45_1) 2009; 13
e_1_2_9_9_1
e_1_2_9_25_1
e_1_2_9_27_1
e_1_2_9_48_1
e_1_2_9_29_1
References_xml – volume: 485
  start-page: 23
  year: 2017
  end-page: 29
  article-title: Rifampicin pre‐treatment inhibits the toxicity of rotenone‐induced PC12 cells by enhancing sumoylation modification of α‐synuclein
  publication-title: Biochem. Biophys. Res. Commun.
– volume: 1139
  start-page: 220
  year: 2007
  end-page: 225
  article-title: Rifampicin protects PC12 cells against MPP+‐induced apoptosis and inhibits the expression of an alpha‐Synuclein multimer
  publication-title: Brain Res.
– volume: 1502
  start-page: 76
  year: 2000
  end-page: 84
  article-title: Approaches to discovery and characterization of inhibitors of amyloid beta‐peptide polymerization
  publication-title: Biochim. Biophys. Acta
– volume: 106
  start-page: 1489
  year: 2000
  end-page: 1499
  article-title: Clearance of Alzheimer's amyloid‐ss(1–40) peptide from brain by LDL receptor‐related protein‐1 at the blood‐brain barrier
  publication-title: J. Clin. Invest.
– volume: 108
  start-page: 65
  year: 2004
  end-page: 68
  article-title: Rifampicin inhibits neurodegeneration in the optic nerve transection model in vivo and after 1‐methyl‐4‐phenylpyridinium intoxication in vitro
  publication-title: Acta Neuropathol.
– volume: 11
  start-page: 1513
  year: 2004
  end-page: 1521
  article-title: Rifampicin inhibits alpha‐synuclein fibrillation and disaggregates fibrils
  publication-title: Chem. Biol.
– volume: 335
  start-page: 330
  year: 1996
  end-page: 336
  article-title: Evaluation of dementia
  publication-title: N. Engl. J. Med.
– volume: 81
  start-page: 434
  year: 2002
  end-page: 440
  article-title: Nordihydroguaiaretic acid potently breaks down pre‐formed Alzheimer's beta‐amyloid fibrils in vitro
  publication-title: J. Neurochem.
– volume: 17
  start-page: 347
  year: 2007
  end-page: 353
  article-title: MDR1‐P‐glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid‐β peptides: Implications for the mechanisms of Aβ clearance at the blood–brain barrier
  publication-title: Brain Pathol.
– volume: 63
  start-page: 1111
  year: 2011
  end-page: 1118
  article-title: Up‐regulation of P‐glycoprotein reduces intracellular accumulation of beta amyloid: Investigation of P‐glycoprotein as a novel therapeutic target for Alzheimer's disease
  publication-title: J. Pharm. Pharmacol.
– volume: 143
  start-page: 657
  year: 1995
  end-page: 663
  article-title: Cytokines and inflammatory proteins in Alzheimer's disease
  publication-title: Res. Immunol.
– volume: 340
  start-page: 1970
  year: 1999
  end-page: 1980
  article-title: Molecular basis of the neurodegenerative disorders
  publication-title: N. Engl. J. Med.
– volume: 47
  start-page: 6016
  year: 2008
  end-page: 6024
  article-title: Rifampicin does not prevent amyloid fibril formation by human islet amyloid polypeptide but does inhibit fibril thioflavin‐T interactions: Implications for mechanistic studies of beta‐cell death
  publication-title: Biochemistry
– volume: 8
  start-page: 37
  year: 2017
  end-page: 43
  article-title: Alzheimer's disease as an inflammatory disease
  publication-title: Biomol. Concepts
– volume: 16
  start-page: 276
  year: 1996
  end-page: 284
  article-title: Cytokine‐stimulated astrocytes damage human neurons via a nitric oxide mechanism
  publication-title: Glia
– volume: 34
  start-page: 137
  year: 2013
  end-page: 141
  article-title: Rifampicin and Parkinson's disease
  publication-title: Neurol. Sci.
– volume: 23
  start-page: 698
  year: 2007
  end-page: 706
  article-title: Inhibition of amyloid fibrillization of hen egg‐white lysozymes by rifampicin and p‐benzoquinone
  publication-title: Biotechnol. Prog.
– volume: 107
  start-page: 37
  year: 2014
  end-page: 42
  article-title: Rifampicin: An antibiotic with brain protective function
  publication-title: Brain Res. Bull.
– volume: 3
  start-page: 108
  year: 1978
  end-page: 127
  article-title: Clinical pharmacokinetics of rifampicin
  publication-title: Clin. Pharmacokinet.
– volume: 7
  start-page: 204
  year: 2017
  end-page: 214
  article-title: Preventive effect of rifampicin on Alzheimer disease needs at least 450 mg daily for 1 year: An FDG‐PET follow‐up study
  publication-title: Dement. Geriatr. Cogn. Dis. Extra
– volume: 13
  start-page: 615
  year: 2016
  end-page: 620
  article-title: A role for P‐glycoprotein in clearance of Alzheimer amyloid β‐peptide from the brain
  publication-title: Curr. Alzheimer Res.
– volume: 165
  start-page: 28
  year: 1999
  end-page: 30
  article-title: No effect of anti‐leprosy drugs in the prevention of Alzheimer's disease and beta‐amyloid neurotoxicity
  publication-title: J. Neurol. Sci.
– volume: 13
  start-page: 475
  year: 2009
  end-page: 482
  article-title: Rifampicin inhibits the LPS‐induced expression of Toll‐like Receptor 2 via the suppression of NF‐kappaB DNA‐binding activity in RAW 264.7 cells
  publication-title: Korean J. Physiol. Pharmacol.
– volume: 52
  start-page: 381
  year: 2004
  end-page: 387
  article-title: Randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease
  publication-title: J. Am. Geriatr. Soc.
– volume: 391
  start-page: 387
  year: 1998
  end-page: 390
  article-title: Deficiency of presenilin‐1 inhibits the normal cleavage of amyloid precursor protein
  publication-title: Nature
– volume: 322
  start-page: 859
  year: 1997
  end-page: 865
  article-title: Rifampicin inhibits the toxicity of pre‐aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid–cell interaction
  publication-title: Biochem. J.
– volume: 277
  start-page: 1389
  year: 2010
  end-page: 1409
  article-title: Animal models of amyloid‐beta‐related pathologies in Alzheimer's disease
  publication-title: FEBS J.
– volume: 6
  start-page: 93
  year: 2014
  article-title: The low‐density lipoprotein receptor‐related protein 1 and amyloid‐β clearance in Alzheimer's disease
  publication-title: Front. Aging Neurosci.
– volume: 288
  start-page: 24
  year: 2015
  end-page: 36
  article-title: Memory recuperative potential of rifampicin in aluminum chloride‐induced dementia: Role of pregnane X receptors
  publication-title: Neuroscience
– volume: 3
  start-page: 256
  year: 2005
  end-page: 270
  article-title: The pathophysiology in Alzheimer's disease and directions in treatment
  publication-title: Adv. Stud. Nurs.
– volume: 18
  start-page: 459
  year: 2005
  end-page: 465
  article-title: Differential effects of oligomeric and fibrillar amyloid‐beta 1‐42 on astrocyte‐mediated inflammation
  publication-title: Neurobiol. Dis.
– volume: 96
  start-page: 529
  year: 2011
  end-page: 543
  article-title: The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease
  publication-title: Neurobiol. Learn. Mem.
– volume: 285
  start-page: 7619
  year: 2010
  end-page: 7632
  article-title: Inhibition of calcineurin‐mediated endocytosis and alpha‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer‐induced synaptic disruption
  publication-title: J. Biol. Chem.
– volume: 14
  start-page: 236
  year: 2011
  end-page: 248
  article-title: Exposure of LS‐180 cells to drugs of diverse physicochemical and therapeutic properties up‐regulates P‐glycoprotein expression and activity
  publication-title: J. Pharm. Pharm. Sci.
– volume: 28
  start-page: 463
  year: 2013
  end-page: 470
  article-title: DARAD Study Group. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: The DARAD trial
  publication-title: Int. J. Geriatr. Psychiatry
– volume: 13
  start-page: 12
  year: 2011
  end-page: 20
  article-title: Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation
  publication-title: Brain Res.
– volume: 17
  start-page: 7736
  year: 1997
  end-page: 7745
  article-title: Aggregated amyloid‐beta protein induces cortical neuronal apoptosis and concomitant “apoptotic” pattern of gene induction
  publication-title: J. Neurosci.
– volume: 267
  start-page: 18210
  year: 1992
  end-page: 18217
  article-title: Amyloidogenicity of beta A4 and beta A4‐bearing amyloid protein precursor fragments by metal‐catalyzed oxidation
  publication-title: J. Biol. Chem.
– volume: 77
  start-page: 715
  year: 2010
  end-page: 723
  article-title: Restoring blood‐brain barrier P‐glycoprotein reduces brain amyloid‐beta in a mouse model of Alzheimer's disease
  publication-title: Mol. Pharmacol.
– volume: 66
  start-page: 739
  year: 2010
  end-page: 754
  article-title: Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5
  publication-title: Neuron
– volume: 139
  start-page: 1568
  year: 2016
  end-page: 1586
  article-title: Rifampicin is a candidate preventive medicine against amyloid‐β and tau oligomers
  publication-title: Brain
– volume: 73
  start-page: 174
  year: 2013
  end-page: 182
  article-title: Antibiotics acting as neuroprotectants via mechanisms independent of their anti‐infective activities
  publication-title: Neuropharmacology
– volume: 31
  start-page: 731
  year: 1993
  end-page: 737
  article-title: Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats
  publication-title: J. Antimicrob. Chemother.
– volume: 19
  start-page: 1271
  year: 2008
  end-page: 1276
  article-title: Rifampicin reduces alpha‐synuclein in a transgenic mouse model of multiple system atrophy
  publication-title: Neuroreport
– volume: 14
  start-page: 656
  year: 2017
  end-page: 667
  article-title: Lack of P‐glycoprotein results in impairment of removal of beta‐amyloid and increased intraparenchymal cerebral amyloid angiopathy after active immunization in a transgenic mouse model of Alzheimer's disease
  publication-title: Curr. Alzheimer Res.
– volume: 351
  start-page: 56
  year: 2004
  end-page: 67
  article-title: Alzheimer's disease
  publication-title: N. Engl. J. Med.
– volume: 57
  start-page: 178
  year: 2008
  end-page: 201
  article-title: The blood‐brain barrier in health and chronic neurodegenerative disorders
  publication-title: Neuron
– volume: 13
  start-page: 1029
  year: 2007
  end-page: 1031
  article-title: Clearance of amyloid‐beta by circulating lipoprotein receptors
  publication-title: Nat. Med.
– volume: 13
  start-page: 268
  year: 2014
  end-page: 275
  article-title: Efficacy and safety of rifampicin for multiple system atrophy: A randomised, double‐blind, placebo‐controlled trial
  publication-title: Lancet Neurol.
– volume: 256
  start-page: 184
  year: 1992
  end-page: 185
  article-title: Alzheimer's disease: The amyloid cascade hypothesis
  publication-title: Science
– volume: 55
  start-page: 1106
  year: 2014
  end-page: 1111
  article-title: Activity of P‐glycoprotein, a beta‐amyloid transporter at the blood‐brain barrier, is compromised in patients with mild Alzheimer disease
  publication-title: J. Nucl. Med.
– volume: 155
  start-page: 853
  year: 1999
  end-page: 862
  article-title: Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease
  publication-title: Am. J. Pathol.
– volume: 1762
  start-page: 575
  year: 2006
  end-page: 586
  article-title: Anti‐amyloidogenic effects of antioxidants: Implications for the prevention and therapeutics of Alzheimer's disease
  publication-title: Biochim. Biophys. Acta
– volume: 126
  start-page: 479
  year: 2013
  end-page: 497
  article-title: The amyloid cascade‐inflammatory hypothesis of Alzheimer disease: Implications for therapy
  publication-title: Acta Neuropathol.
– volume: 104
  start-page: 901
  year: 2001
  end-page: 912
  article-title: Structural mechanism for rifampicin inhibition of bacterial RNA polymerase
  publication-title: Cell
– volume: 66
  start-page: 45
  year: 2011
  end-page: 54
  article-title: Insights into Alzheimer disease pathogenesis from studies in transgenic animal models
  publication-title: Clinics (Sao Paulo)
– volume: 340
  start-page: 978
  year: 1992
  article-title: Neurofibrillary tangles and senile plaques in brain of elderly leprosy patients
  publication-title: Lancet
– volume: 89
  start-page: 807
  year: 2004
  end-page: 811
  article-title: Clearing amyloid through the blood‐brain barrier
  publication-title: J. Neurochem.
– volume: 91
  start-page: 3270
  year: 1994
  end-page: 3274
  article-title: A model for beta‐amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– volume: 12
  start-page: 535
  year: 2002
  end-page: 541
  article-title: Deposition of Alzheimer's beta‐amyloid is inversely correlated with P‐glycoprotein expression in the brains of elderly non‐demented humans
  publication-title: Pharmacogenetics
– volume: 4
  start-page: 191
  year: 2007
  end-page: 197
  article-title: Role of the blood‐brain barrier in the pathogenesis of Alzheimer's disease
  publication-title: Curr. Alzheimer Res.
– volume: 115
  start-page: 3285
  year: 2005
  end-page: 3290
  article-title: P‐glycoprotein deficiency at the blood–brain barrier increases amyloid‐beta deposition in an Alzheimer disease mouse model
  publication-title: J. Clin. Invest.
– volume: 271
  start-page: 6839
  year: 1996
  end-page: 6845
  article-title: Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin: Its possible function as a hydroxyl radical scavenger
  publication-title: J. Biol. Chem.
– volume: 204
  start-page: 76
  year: 1994
  end-page: 83
  article-title: Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro
  publication-title: Biochem. Biophys. Res. Commun.
– volume: 76
  start-page: 1121
  year: 2001
  end-page: 1128
  article-title: Beta‐amyloid efflux mediated by p‐glycoprotein
  publication-title: J. Neurochem.
– volume: 65
  start-page: 664
  year: 1999
  end-page: 670
  article-title: Early‐onset autosomal dominant Alzheimer disease: Prevalence, genetic heterogeneity, and mutation spectrum
  publication-title: Am. J. Hum. Genet.
– volume: 31
  start-page: 151
  year: 2012
  end-page: 165
  article-title: Enhanced brain amyloid‐β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease
  publication-title: J. Alzheimers Dis.
– ident: e_1_2_9_40_1
  doi: 10.1097/WNR.0b013e32830b3661
– ident: e_1_2_9_18_1
  doi: 10.1016/j.nbd.2004.12.013
– volume: 13
  start-page: 475
  year: 2009
  ident: e_1_2_9_45_1
  article-title: Rifampicin inhibits the LPS‐induced expression of Toll‐like Receptor 2 via the suppression of NF‐kappaB DNA‐binding activity in RAW 264.7 cells
  publication-title: Korean J. Physiol. Pharmacol.
  doi: 10.4196/kjpp.2009.13.6.475
– ident: e_1_2_9_25_1
  doi: 10.2174/156720507780362245
– ident: e_1_2_9_63_1
  doi: 10.1016/S0022-510X(99)00057-X
– ident: e_1_2_9_2_1
  doi: 10.1056/NEJM199608013350507
– volume: 267
  start-page: 18210
  year: 1992
  ident: e_1_2_9_15_1
  article-title: Amyloidogenicity of beta A4 and beta A4‐bearing amyloid protein precursor fragments by metal‐catalyzed oxidation
  publication-title: J. Biol. Chem.
  doi: 10.1016/S0021-9258(19)37174-1
– ident: e_1_2_9_60_1
  doi: 10.3389/fnagi.2014.00093
– ident: e_1_2_9_32_1
  doi: 10.1124/mol.109.061754
– ident: e_1_2_9_33_1
  doi: 10.2174/1567205013666160314151012
– ident: e_1_2_9_10_1
  doi: 10.1523/JNEUROSCI.17-20-07736.1997
– ident: e_1_2_9_53_1
  doi: 10.1093/brain/aww042
– ident: e_1_2_9_57_1
  doi: 10.2174/1567205013666161201201227
– volume: 3
  start-page: 256
  year: 2005
  ident: e_1_2_9_14_1
  article-title: The pathophysiology in Alzheimer's disease and directions in treatment
  publication-title: Adv. Stud. Nurs.
– ident: e_1_2_9_59_1
  doi: 10.18433/J36016
– ident: e_1_2_9_37_1
  doi: 10.1016/S0092-8674(01)00286-0
– ident: e_1_2_9_49_1
  doi: 10.1016/S0925-4439(00)00034-X
– ident: e_1_2_9_5_1
  doi: 10.1002/(SICI)1098-1136(199603)16:3<276::AID-GLIA10>3.0.CO;2-X
– ident: e_1_2_9_47_1
  doi: 10.1006/bbrc.1994.2428
– ident: e_1_2_9_46_1
  doi: 10.1007/s10072-012-1156-0
– ident: e_1_2_9_38_1
  doi: 10.1016/j.bbrc.2017.01.100
– ident: e_1_2_9_42_1
  doi: 10.1016/j.chembiol.2004.08.025
– ident: e_1_2_9_51_1
  doi: 10.1046/j.1471-4159.2002.00904.x
– ident: e_1_2_9_20_1
  doi: 10.1016/j.neuron.2010.04.029
– ident: e_1_2_9_56_1
  doi: 10.1111/j.1750-3639.2007.00075.x
– ident: e_1_2_9_3_1
  doi: 10.1515/bmc-2016-0029
– ident: e_1_2_9_68_1
  doi: 10.1159/000477343
– ident: e_1_2_9_29_1
  doi: 10.1172/JCI10498
– ident: e_1_2_9_35_1
  doi: 10.2165/00003088-197803020-00002
– volume: 13
  start-page: 12
  year: 2011
  ident: e_1_2_9_43_1
  article-title: Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation
  publication-title: Brain Res.
  doi: 10.1016/j.brainres.2011.04.019
– ident: e_1_2_9_8_1
  doi: 10.1016/j.neuropharm.2013.04.059
– volume: 143
  start-page: 657
  year: 1995
  ident: e_1_2_9_4_1
  article-title: Cytokines and inflammatory proteins in Alzheimer's disease
  publication-title: Res. Immunol.
  doi: 10.1016/0923-2494(92)80052-M
– ident: e_1_2_9_65_1
  doi: 10.1016/0140-6736(92)92870-L
– ident: e_1_2_9_62_1
  doi: 10.1016/j.neuroscience.2014.12.033
– ident: e_1_2_9_44_1
  doi: 10.1007/s00401-004-0867-6
– ident: e_1_2_9_52_1
  doi: 10.1016/j.bbadis.2006.03.002
– ident: e_1_2_9_48_1
  doi: 10.1042/bj3220859
– ident: e_1_2_9_12_1
  doi: 10.1111/j.1742-4658.2010.07564.x
– ident: e_1_2_9_26_1
  doi: 10.1016/j.neuron.2008.01.003
– ident: e_1_2_9_22_1
  doi: 10.1056/NEJM199906243402507
– ident: e_1_2_9_7_1
  doi: 10.1016/j.brainresbull.2014.05.007
– ident: e_1_2_9_54_1
  doi: 10.1046/j.1471-4159.2001.00113.x
– ident: e_1_2_9_30_1
  doi: 10.1097/00008571-200210000-00005
– ident: e_1_2_9_11_1
  doi: 10.1126/science.1566067
– ident: e_1_2_9_27_1
  doi: 10.1111/j.1471-4159.2004.02385.x
– ident: e_1_2_9_31_1
  doi: 10.2967/jnumed.113.130161
– ident: e_1_2_9_16_1
  doi: 10.1073/pnas.91.8.3270
– ident: e_1_2_9_17_1
  doi: 10.1016/j.nlm.2011.08.003
– ident: e_1_2_9_67_1
  doi: 10.1002/gps.3846
– ident: e_1_2_9_39_1
  doi: 10.1016/S1474-4422(13)70301-6
– ident: e_1_2_9_9_1
  doi: 10.1590/S1807-59322011001300006
– ident: e_1_2_9_34_1
  doi: 10.1074/jbc.271.12.6839
– ident: e_1_2_9_55_1
  doi: 10.1172/JCI25247
– ident: e_1_2_9_21_1
  doi: 10.1038/34910
– ident: e_1_2_9_24_1
  doi: 10.1086/302553
– ident: e_1_2_9_58_1
  doi: 10.1111/j.2042-7158.2011.01309.x
– ident: e_1_2_9_6_1
  doi: 10.1007/s00401-013-1177-7
– ident: e_1_2_9_50_1
  doi: 10.1021/bp060353n
– ident: e_1_2_9_41_1
  doi: 10.1016/j.brainres.2006.12.074
– ident: e_1_2_9_28_1
  doi: 10.1038/nm1635
– ident: e_1_2_9_19_1
  doi: 10.1074/jbc.M109.057182
– ident: e_1_2_9_66_1
  doi: 10.1111/j.1532-5415.2004.52109.x
– ident: e_1_2_9_64_1
  doi: 10.1021/bi702518m
– ident: e_1_2_9_13_1
  doi: 10.1056/NEJMra040223
– ident: e_1_2_9_61_1
  doi: 10.3233/JAD-2012-120319
– ident: e_1_2_9_36_1
  doi: 10.1093/jac/31.5.731
– ident: e_1_2_9_23_1
  doi: 10.1016/S0002-9440(10)65184-X
SSID ssj0003361
Score 2.4367292
SecondaryResourceType review_article
Snippet Rifampicin exerts significant brain protective functions in multiple experimental models. Here we summarize the underlying mechanisms of the neuroprotective...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 152
SubjectTerms Alzheimer Disease - drug therapy
Alzheimer's disease
amyloid beta clearance
Cognitive ability
Humans
Inflammation
Neurodegenerative diseases
Neuroimaging
Neuroprotection
Neuroprotective Agents - pharmacology
Nootropic Agents - pharmacology
oligomeric amyloid hypothesis
rifampicin
Rifampin
Rifampin - pharmacology
Tau protein
Title Therapeutic role of rifampicin in Alzheimer's disease
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fpcn.12637
https://www.ncbi.nlm.nih.gov/pubmed/29315976
https://www.proquest.com/docview/2011140844
https://www.proquest.com/docview/1989558319
Volume 72
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JS8UwEB7Eg3hxX54bVQS99GGbJk3xJC64oIgoeBBKJk3wofY93nLx1zvp5g4i9FDolEyTzOSbzuQLwLaRjlSKWz9gkfYjoRI_4TbzyTEitzIj-3OB4uWVOL2Lzu_5_Rjs13thSn6I5oebs4zCXzsDVzj4YOQ9nbeDUDC3kzxgwvHmH928U0cxJqpgi5EegahYhVwVT_Pm57XoG8D8jFeLBedkGh5qVcs6k6f2aIht_fqFxfGf3zIDUxUQ9Q7KmTMLYyafg4nLKtU-D_z2fWeW52oQva71-h2rXnpOwqPr4Pn10XReTH9n4FWJngW4Ozm-PTz1qzMWfO1oefwgCxQKHsZKosY9LoXNJFOoCadgROBGsRhjhu68OxuHJlGMIKANkzhBQlaGLcJ43s3NMnhIWCEOeYg2URFiJLM9lWhqBpXOyL-3YLfu7VRXBOTuHIzntA5EqBvSohtasNWI9krWjZ-E1uohSyvDG6QOz1DMKKOoBZvNYzIZlwdRuemOBqkrE-NckvNpwVI51E0rhH4I4MWClC0G7Pfm0-vDq-Jm5e-iqzBJCsqyhm0Nxof9kVknUDPEDZq9ZxcbxRx-A-rL8NU
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZS8QwEB48QH3xPtaziqAvXbZN06bgyyLKeuwisoIvUpI0wcW1u-zx4q930ms9QYQ-FDol0yQz_SYz-QJwrJghlaLadognbc_noR1SHdvoGAXVLEb7M4Fis-U3HrzrR_o4BWfFXpiMH6JccDOWkfprY-BmQfqDlfdlUnVcnwTTMJvm5wwkup-QRxHi5-EWQU0cP-cVMnU85auf_0bfIOZnxJr-ci6X4KlQNqs0eamOR6Iq377wOP73a5ZhMceiVj2bPCswpZJVmGvm2fY1oO3J5izLlCFaPW0NOpq_9o2EhVe9-_asOq9qcDK08lzPOjxcXrTPG3Z-zIItDTOP7cQOFz51A86EFDXKfB0zwoVEqCI8xDecBCIgwhx5pwNXhZwgCtRuGIQCwZUiGzCT9BK1BZZAuBC41BU65J4QHotrPJTYjOAyRhdfgdOiuyOZc5CbozC6URGLYDdEaTdU4KgU7WfEGz8J7RZjFuW2N4wMpMGwkXleBQ7Lx2g1JhXCE9UbDyNTKUYpQ_9Tgc1srMtWEAAhxgt8VDYdsd-bj-7OW-nN9t9FD2C-0W7eRrdXrZsdWEBlWVbStgszo8FY7SHGGYn9dCq_A1LW8_o
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS-wwEB50BfHF-zmu1yoHPC9dts2lKT6Junhd5KDgg1CSNOGIbnfZy4u_3klv6jkKIvSh0CmZTjKTb5rJF4BfRjhSKWb9gFDtUy5jP2Y29TEwKmZFiv7nEsWrLj-9ped37G4KDqq9MAU_RP3DzXlGHq-dgw9S-8bJBzprBSEn0TTMUI7TpENEf165owjhZbZFUJGAl7RCroynfvX9ZPQfwnwPWPMZp7MA95WuRaHJY2syVi39_A-N4zc_ZhHmSyTqHRZDZwmmTLYMs1flWvsKsJvXrVmeK0L0-tYbPljZGzgJD6_Dp-e_5qFnhvsjr1zpWYXbzsnN0alfHrLga8fL4wdpIBVnYSSF0qrNBLepIFJpBCqKIrqRJFIRUe7AOxuFJpYEMaAN4yhWCK0M-QGNrJ-ZNfAUgoUoZKGysaRKUZG2ZayxGSV1igG-Cb8raye6ZCB3B2E8JVUmgmZIcjM0Ya8WHRS0Gx8JbVZdlpSeN0ocoMGkUVDahN36MfqMWwiRmelPRomrE2NMYPRpws-iq-tWEP4gwos4Kpt32OfNJ9dH3fxm_euiOzB7fdxJLs-6Fxswh7qKop5tExrj4cRsIcAZq-18IL8AgJjyqQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+role+of+rifampicin+in+Alzheimer%27s+disease&rft.jtitle=Psychiatry+and+clinical+neurosciences&rft.au=Yulug%2C+Burak&rft.au=Hanoglu%2C+L%C3%BCtf%C3%BC&rft.au=Ozansoy%2C+Mehmet&rft.au=Is%C4%B1k%2C+Dogan&rft.date=2018-03-01&rft.issn=1323-1316&rft.eissn=1440-1819&rft.volume=72&rft.issue=3&rft.spage=152&rft.epage=159&rft_id=info:doi/10.1111%2Fpcn.12637&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_pcn_12637
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1323-1316&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1323-1316&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1323-1316&client=summon